Fulgent Genetic (NASDAQ: FLGT) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its competitors? We will compare Fulgent Genetic to similar companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.
This table compares Fulgent Genetic and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Fulgent Genetic Competitors||-327.89%||-35.26%||-12.41%|
Earnings & Valuation
This table compares Fulgent Genetic and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Fulgent Genetic||$20.81 million||$2.17 million||-11.37|
|Fulgent Genetic Competitors||$2.02 billion||$430.74 million||-70.34|
Fulgent Genetic’s competitors have higher revenue and earnings than Fulgent Genetic. Fulgent Genetic is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
16.8% of Fulgent Genetic shares are owned by institutional investors. Comparatively, 53.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 17.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations for Fulgent Genetic and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Fulgent Genetic Competitors||253||1813||3257||105||2.59|
Fulgent Genetic presently has a consensus target price of $10.67, indicating a potential upside of 146.91%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.90%. Given Fulgent Genetic’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Fulgent Genetic is more favorable than its competitors.
Fulgent Genetic beats its competitors on 6 of the 11 factors compared.
Fulgent Genetic Company Profile
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.